Bayesian Dose Escalation Designs for Late Onset Toxicity

Posted by Cytel

Nov 10, 2015 4:00:00 PM

Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods in early phase oncology. 

Li Liu, the Assistant Director of Biostatistics at Sanofi, kicked off the day with this talk on Bayesian dose-escalation designs with considerations for late onset toxicity. Li shows that in order to account for both dose-limiting toxicity and late onset toxicity, trial designs may have to  move beyond the standard use of escalation with overdose control (EWOC). 

Click to watch how incorporating Bayesian strategies can help overcome this common problem. 


Topics: Dose-Escalation, Bayesian Methods

The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.


Posts by Topic

see all

Recent Posts